WA
SRPT icon

WFG Advisors’s Sarepta Therapeutics SRPT Stock Holding History

WFG Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$5K Buy
+145
New +$4.72K ﹤0.01% 1293

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WFG Advisors's SRPT Position: Q2 2017 in Review

WFG Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2017: 145 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #1293 among its holdings.

189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • WFG Advisors held 145 shares of Sarepta Therapeutics worth $5K as of Q2 2017.
  • Sarepta Therapeutics was a new WFG Advisors position in Q2 2017.
  • Sarepta Therapeutics made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1293 holding.
  • 189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.